Clinical trial · Observational
Implementation of New Models of Ovarian Carcinoma Resistant to Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project focuses on developing new experimental models of ovarian cancer that accurately reflect patients who do not respond to first-line platinum-based treatments and who are resistant to PARP inhibitors (PARPi). These models are essential for testing new drugs or drug combinations in preclinical settings that closely mimic real clinical conditions. These models will also help to identify predictive biomarkers of treatment response and to better understand the biological mechanisms behind therapy resistance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Platinum drugs and PARPi | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with ovarian carcinoma
- description
- Patients with ovarian carcinoma resistant to platinum drugs and PARPi
- interventionNames
- Other: Platinum drugs and PARPi
Primary outcomes (2)
- measure
- To obtain new in vivo experimental models of ovarian carcinomas
- timeFrame
- 10 years
- description
- To obtain new experimental models from biopsies of ovarian carcinomas that are refractory to platinum-based therapy and recurrent during or after treatment with platinum-based therapy and PARP inhibitors, as treated at the Division of Medical Gynecologic Oncology of the European Institute of Oncology. To this end, a portion of the neoplastic tissue will be transplanted subcutaneously into at least two immunodeficient mice and follwed for tumor appearance
- measure
- To obtain new in vitro experimental models of ovarian carcinomas
- timeFrame
- 10 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients with malignant ovarian gynecological disease. * Age 18 years or older. * Patients capable of providing informed consent. Exclusion Criteria: -Failure to sign the informed consent form.
References
Publications (0)
Data not yet available